Health Information Framing, Source Characteristics, and Health Behavior Promotion
NCT07927387, Not applicable, Not yet recruiting, Peking University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Health Information Framing, Source Characteristics, and Health Behavior Promotion | ClinicalTrials.gov |
| NCT number | NCT07927387 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 102,000 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Peking University | ClinicalTrials.gov |
| Conditions | Vaccination, Mental Health, Health Behavior, Health Communication | ClinicalTrials.gov |
| Interventions | AI-sourced gain-framed message (Component 1), AI-sourced loss-framed message (Component 1), AI-sourced normative message (Component 1), AI-sourced structured message (Component 1), AI-sourced expert-authority message (Component 1), Official gain-framed message (Component 1), Official loss-framed message (Component 1), Official normative message (Component 1), Official structured message (Component 1), Official expert-authority message (Component 1), Gain-framed peer message (Component 2), Gain-framed expert message (Component 2), Loss-framed peer message (Component 2), Loss-framed expert message (Component 2), Social-norm message (Component 2) | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | HPV vaccination intention | Immediately after exposure to the assigned health information condition (post-exposure questionnaire). | In the Hunan population, assessed immediately after exposure with one 5-point item: "I am willing to receive the HPV vaccine in the future." Responses range from 1 (strongly disagree) to 5 (strongly agree). Higher scores indicate stronger intention to receive the HPV vaccine. | ClinicalTrials.gov |
| Primary | Professional mental health help-seeking intention | Immediately after exposure to the assigned health information condition (post-exposure questionnaire). | In Tongzhou students and primary caregivers, assessed using three 7-point items asking how likely the participant would be to seek help from a psychologist, a psychiatrist, and another doctor if experiencing persistent emotional distress or thoughts of self-harm. Scores range from 1 (definitely would not) to 7 (definitely would). The mean of the three items will be calculated; higher scores indicate stronger professional help-seeking intention. | ClinicalTrials.gov |
| Primary | HPV vaccination booking-directed action | During the same online session immediately after exposure to the assigned health information condition. | In the Hunan population, a binary behavioral outcome recorded by the online questionnaire platform after exposure. A positive response is defined as either selecting direct booking at the first decision point or agreeing to provide contact information for HPV vaccination booking at the end of the booking pathway. Viewing information without proceeding to booking or providing contact information is not counted as a positive response. | ClinicalTrials.gov |
| Secondary | HPV vaccine trust | Immediately after exposure to the assigned health information condition. | In the Hunan population, assessed with five HPV-adapted Vaccine Trust Gauge items covering vaccine safety, protection against serious illness, relative health risk, benefits versus risks, and effectiveness. Responses will be scored in the direction of greater trust using the prespecified VTG scoring and missing response rules. The item mean will be rescaled to 0-100; higher scores indicate greater trust. | ClinicalTrials.gov |
| Secondary | Trust in HPV vaccine information sources | Immediately after exposure to the assigned health information condition. | In the Hunan population, assessed with five Vaccine Trust Gauge-adapted items measuring trust in HPV vaccine recommendations from schools or official institutions, doctors or nurses, family or friends, classmates or peers, and social media. Responses will be scored using the same prespecified VTG rules. The item mean will be rescaled to 0-100; higher scores indicate greater trust. | ClinicalTrials.gov |
| Secondary | HPV vaccination readiness (7C-based) | Immediately after exposure to the assigned health information condition. | In the Hunan population, assessed using seven HPV-adapted 7C vaccination- readiness items covering calculation, collective responsibility, confidence in the system, confidence in vaccine safety, social conformity, convenience or constraints, and complacency. Items will be reverse scored where required and averaged so that higher scores indicate greater vaccination readiness. | ClinicalTrials.gov |
| Secondary | Perceived susceptibility to HPV infection | Immediately after exposure to the assigned health information condition. | In the Hunan population, assessed using the mean of three 5-point Health Belief Model items representing perceived susceptibility to HPV infection. Items will be reverse scored as specified in the analysis plan so that higher scores indicate greater perceived susceptibility. | ClinicalTrials.gov |
| Secondary | Perceived severity of HPV infection | Immediately after exposure to the assigned health information condition. | In the Hunan population, assessed using one reverse-scored 5-point Health Belief Model item concerning whether the health effects of HPV infection are not serious. The score will be transformed so that higher scores indicate greater perceived severity. | ClinicalTrials.gov |
| Secondary | Perceived barriers to HPV vaccination | Immediately after exposure to the assigned health information condition. | In the Hunan population, assessed using the mean of six 5-point Health Belief Model items concerning perceived drawbacks, cost, insufficient information, uncertain long-term side effects, sexual stigma, and sensitivity of the topic. Higher scores indicate greater perceived barriers to HPV vaccination. | ClinicalTrials.gov |
| Secondary | Cues to action for HPV vaccination | Immediately after exposure to the assigned health information condition. | In the Hunan population, assessed using the mean of two 5-point Health Belief Model items concerning exposure to media reports promoting HPV vaccination and the influence of a doctor's recommendation. Higher scores indicate stronger cues to action. | ClinicalTrials.gov |
| Secondary | Help-seeking efficacy attitudes related to mental health | Immediately after exposure to the assigned school-based health message. | In Tongzhou students and primary caregivers, assessed using the Help-Seeking dimension of the Universal Mental Health Literacy Scale for Adolescents (UMHL-A). Five applicable items are used in students and four in caregivers. Items are scored on a 5-point scale, averaged, and rescaled to 0-100. Higher scores indicate more favorable help-seeking attitudes. | ClinicalTrials.gov |
| Secondary | Stigma-related attitudes toward mental health | Immediately after exposure to the assigned school-based health message. | In Tongzhou students and primary caregivers, assessed using the three-item Stigma dimension of the Universal Mental Health Literacy Scale for Adolescents (UMHL-A). Items are scored on a 5-point scale, averaged, and rescaled to 0-100 in the direction of less stigmatizing and more favorable attitudes. | ClinicalTrials.gov |
| Secondary | Intention to use generative AI for HPV vaccination information | Immediately after exposure to the assigned health information condition. | In the Hunan population, assessed using two post-exposure 5-point items asking whether the participant is willing to use an AI chatbot to obtain further HPV vaccination information and whether generative AI would be used as one source of HPV vaccination information. Both items will be coded in the direction of greater intention and averaged. | ClinicalTrials.gov |
| Secondary | Benevolence dimension of trust in generative AI for health information | Immediately after exposure to the assigned health information condition. | In Hunan and Tongzhou participants, assessed using the three-item Benevolence dimension of the Human-Generative AI Trust Scale, adapted to HPV vaccination or mental health information. The items assess whether generative AI acts in the participant's best interest, is willing to understand the participant's needs and preferences, and will help to the best of its ability. Items use a 5-point response scale and are averaged; higher scores indicate greater benevolence-based trust. | ClinicalTrials.gov |
| Secondary | Competence dimension of trust in generative AI for health information | Immediately after exposure to the assigned health information condition. | In Hunan and Tongzhou participants, assessed using the three-item Competence dimension of the Human-Generative AI Trust Scale. The items assess whether generative AI can effectively support the participant in understanding health information, performs well in providing health information support, and has the expected functions for that role. Items use a 5-point response scale and are averaged; higher scores indicate greater competence-based trust. | ClinicalTrials.gov |
| Secondary | Reciprocity or dependency dimension of trust in generative AI for health information | Immediately after exposure to the assigned health information condition. | In Hunan and Tongzhou participants, assessed using the three-item Reciprocity or Dependency dimension of the Human-Generative AI Trust Scale. The items assess whether participants believe they can rely on generative AI, whether it can continue to support health decisions, and whether they refer to health information provided by generative AI. Items use a 5-point response scale and are averaged; higher scores indicate greater reciprocity-based trust. | ClinicalTrials.gov |
| Secondary | Psychological resilience | Immediately after exposure to the assigned school-based health message. | In Tongzhou students and primary caregivers, assessed immediately after exposure using the 10-item Connor-Davidson Resilience Scale (CD-RISC-10). Each item is scored from 0 (not true at all) to 4 (true nearly all the time). The 10 item scores are summed to a total score ranging from 0 to 40; higher scores indicate greater psychological resilience. If the online platform stores responses as 1-5, scores will be recoded to 0-4 before summation. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)